[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypoxic-ischemic-encephalopathy-hie\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypoxic-ischemic-encephalopathy-hie":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,82,106,176,203,237,267],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100581807","phase-3-caffeine-for-hypoxic-ischemic-encephalopathy-100581807",false,"NCT06855108","Caffeine for Hypoxic Ischemic Encephalopathy","Caffeine for Hypoxic Ischemic Encephalopathy (CHIME Trial)","CHIME","Participant Inclusion Criteria:\n\nInfants who meet all the following criteria are eligible for enrollment as study participants:\n\n1. Liveborn infants ≥36 weeks\n2. Birth weight ≥1800 grams\n3. Meets physiologic criteria for moderate to severe HIE, defined as meeting either of the following two criteria:\n\n   1. Criterion #1: Severe acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria:\n\n      * pH \\\u003C7.0; or\n      * Base Deficit ≥16 mmol\u002FL; or\n      * Lactate \\>8 mmol\u002FL.\n   2. Criterion #2: Participant must meet all of the following three criteria:\n\n   i. Moderate acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria:\n   * POC pH 7.0-7.15; or\n   * Base Deficit 10.0-15.9 mmol\u002FL; or\n   * Lactate 6-8 mmol\u002FL.\n\n   ii. Evidence of an acute perinatal event (i.e., placental abruption, intrapartum hemorrhage, cord prolapse, severe fetal heart rate abnormality, uterine rupture).\n\n   iii. Any of the following criteria:\n   * 10-minute Apgar \\\u003C5; or\n   * Need for assisted ventilation initiated at birth and continued for ≥10 minutes\n4. Meets neurologic criteria for moderate to severe HIE, defined as a physical exam conducted between one and six hours after birth that meets either of the following criteria:\n\n   1. Moderate to severe encephalopathy in at least three out of six modified Sarnat categories (level of consciousness, spontaneous activity, muscle tone, posture, primitive reflexes, autonomic function); or\n   2. A clinical diagnosis of seizure in the first six hours after birth.\n\nParticipant Exclusion Criteria:\n\nInfants who meet any of the following criteria are not eligible for enrollment as study participants:\n\n1. Home births\n2. Infants who cannot be enrolled, randomized and receive study medication within 6 hours post-delivery\n3. Infants with a recognized major congenital anomaly or genetic syndrome that would affect their neurodevelopment.\n4. Infants for whom medical care will not be provided based on the severity of their condition or any other condition that would preclude participation per clinical judgement.\n5. Infant has received therapeutic hypothermia or there is a clinical plan to initiate active or passive hypothermia for the infant.\n6. Infants who will be unavailable to complete follow-up visits.\n7. Infants who have received caffeine after delivery.\n8. Infants whom the health care team deem ineligible for the study based on likelihood to receive caffeine outside of the study protocol.\n9. Enrollment in another trial that will impact participation in this trial.","ALL","6 Hours",{"count":20,"type":21},830,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","CHIME is a randomized, parallel-arm, double-blind, placebo-controlled trial focused on infants with hypoxic ischemic encephalopathy (HIE). The trial will recruit neonates who are diagnosed with HIE within six hours after birth based on physiologic criteria (acidosis noted on an umbilical cord or early \\[\\\u003C1 hour\\] postnatal blood sample) and neurologic criteria (modified Sarnat exam consistent with encephalopathy). Following informed consent, and by six hours after birth, neonates with HIE will be randomized to one of two treatment arms and subsequently receive one 20 mg\u002Fkg dose of oral caffeine followed by two additional 10 mg\u002Fkg doses at 24-hour intervals or placebo of the same regimen (three total doses).\n\nThe goal of this clinical trial is to compare the incidence of all-cause mortality OR moderate to severe neurodevelopmental impairment (NDI) at 18-22 months between neonates with HIE who are randomized to oral caffeine or placebo. Our hypothesis is that neonates with HIE who receive oral caffeine will have 10% lower incidence of all-cause mortality or moderate to severe NDI at 18-22 months compared to placebo.",[27],"Hypoxic Ischemic Encephalopathy (HIE)",[29,30,31,32],"Caffeine","Hypoxic Ischemic Encephalopathy","HIE","AKI","RECRUITING","2026-06-19",{"date":36,"type":37},"2026-06-24","ACTUAL",{"date":39,"type":37},"2026-04-08",{"date":41,"type":21},"2030-07",{"name":43,"class":44},"NICHD Global Network for Women's and Children's Health","NETWORK",7,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100624195","phase-2-the-protect-hie-pilot-trial-100624195","NCT07406477","The PROTECT-HIE Pilot Trial","The PROTECT-HIE Pilot Trial: Prophylactic Therapy to Enhance Cardiovascular Treatment in Neonatal Hypoxemic Ischemic Encephalopathy","PROTECT-HIE","Inclusion Criteria:\n\n* Newborns with hypoxemic ischemic encephalopathy (HIE) receiving therapeutic hypothermia (TH).\n\nExclusion Criteria:\n\n1. Congenital abnormality\n2. known contraindication of dobutamine\n\n   * Left ventricular outflow tract dynamic obstruction\n   * Hypersensitivity to dobutamine\n   * Uncorrected tachyarrhythmias or ventricular fibrillation\n3. Newborns who are already started on inotropes at the time of randomization.\n4. Parental refusal to consent to participate","1 Day",{"count":56,"type":21},40,[58],"PHASE2","Some babies experience a lack of oxygen and blood flow around the time of birth. This can lead to a serious condition called hypoxic-ischemic encephalopathy (HIE), which can injure the brain and other organs, including the heart. To reduce brain injury, babies with HIE are treated with therapeutic hypothermia, a standard treatment in which the baby's body temperature is carefully lowered for several days. While cooling helps protect the brain, many babies with HIE still develop heart problems and low blood flow, which may worsen outcomes.\n\nDoctors often use medications to support the heart and circulation in these babies, but there is no clear agreement on which medication works best or when it should be started. One commonly used medication is dobutamine, which helps the heart pump more effectively. Dobutamine is already used in newborn intensive care units when babies show signs of heart weakness, but it is usually started only after problems develop.\n\nThe PROTECT-HIE trial aims to find out whether it is possible and safe to start dobutamine early, before clear signs of heart failure appear, in newborns with HIE who are receiving therapeutic hypothermia. The idea is that early support of the heart may improve blood flow to vital organs, including the brain, and potentially reduce injury.\n\nIn this study, 40 newborns with HIE will take part at a single neonatal intensive care unit. Babies will be randomly assigned to one of two groups. One group will receive a low, preventative dose of dobutamine within the first four hours after cooling begins. The other group will receive a placebo (an inactive fluid that looks the same). Neither the families nor the medical team assessing outcomes will know which treatment the baby received.\n\nThe main goal of this study is to determine feasibility-that is, whether starting dobutamine early during cooling can be done reliably and safely in this setting. Researchers will also collect information on important health outcomes, such as signs of brain injury on MRI, seizures, need for additional heart medications, heart function on ultrasound, recovery of blood markers, urine output, length of hospital stay, and survival.\n\nBecause HIE is an emergency condition and treatment must start very soon after birth, parents will be approached for consent after the baby has been stabilized. This approach is commonly used in neonatal emergency research and has been approved in similar studies.\n\nThe results of this study will help determine whether a larger trial should be done in the future. Ultimately, this research aims to improve care and outcomes for babies affected by HIE by optimizing support for the heart during a critical period after birth.",[61],"Hypoxic-ischemic Encephalopathy (HIE)",[63,64,65,66,67,68,69],"Hypoxic-ischemic encephalopathy","feasibility RCT","neonatal cardiac dysfunction","prophylactic inotrope","therapeutic hypothermia","neonatal HIE","dobutamine","NOT_YET_RECRUITING","2026-06-03",{"date":73,"type":37},"2026-06-05",{"date":75,"type":21},"2026-07-15",{"date":77,"type":21},"2029-04-30",{"name":79,"class":80},"University of Alberta","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":18,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":81},"100635666","therapeutic-hypothermia-for-neonatal-hypoxic-ischemic-encephalopathy-in-vietnam-100635666","NCT07555652","Therapeutic Hypothermia for Neonatal Hypoxic-Ischemic Encephalopathy in Vietnam","Efficacy of Controlled Therapeutic Hypothermia for Neonatal Hypoxic-Ischemic Encephalopathy (HIE)","HIE-TH Vietnam","Inclusion Criteria:\n\n* Neonates diagnosed with hypoxic-ischemic encephalopathy (HIE) at the Neonatal Center, National Children's Hospital\n* Gestational age ≥ 36 weeks\n* Assessed using the modified Sarnat staging within the first 0-6 hours after birth\n* Eligible for and\u002For treated with therapeutic hypothermia according to institutional protocol\n* Underwent clinical and paraclinical monitoring during hospitalization\n* Received brain magnetic resonance imaging (MRI) during the neonatal period (from 5 to 17 days of age)\n* Availability of complete medical records for data collection and analysis\n\nExclusion Criteria:\n\n* Presence of major congenital anomalies, particularly involving the central nervous system\n* Absence of brain MRI during the study period\n* Refusal of participation by parent(s) or legal guardian(s)","0 Hours",{"count":92,"type":21},120,[94],"NA","This study aims to evaluate the effectiveness of therapeutic hypothermia in neonates diagnosed with hypoxic-ischemic encephalopathy (HIE). The study focuses on assessing both short-term outcomes after treatment and long-term neurological outcomes following therapeutic hypothermia.",[61],"2026-04-21",{"date":99,"type":37},"2026-04-29",{"date":101,"type":37},"2025-06-10",{"date":103,"type":21},"2028-02-01",{"name":105,"class":80},"National Children's Hospital, Vietnam",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":142,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":81},"100630855","intensive-multimodal-neurorehabilitation-targeting-neuroplasticity-in-pediatric-neurodevelopmental-and-chromosomal-disorders-100630855","NCT07493096","Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders","Functional and Neurodevelopmental Outcomes Following Intensive Multimodal Neurorehabilitation in Pediatric Patients With Neurodevelopmental Disorders, Including Chromosomal Abnormalities","GEN-HOPE","Inclusion Criteria:\n\n* Pediatric participants between approximately 4 and 12 years of age at the time of enrollment.\n* Diagnosed with or presenting with neurodevelopmental, neurologic, or genetic conditions, including but not limited to:\n\n  * cerebral palsy\n  * autism spectrum disorder\n  * developmental delay\n  * hypoxic ischemic encephalopathy (HIE)\n  * traumatic brain injury\n  * sensory processing disorder\n  * chromosomal or genetic abnormalities\n  * Demonstrate functional impairments in one or more neurodevelopmental domains, including:\n* motor coordination or motor planning\n* sensory processing\n* attention or executive functioning\n* oculomotor or visual processing\n* communication\n* emotional or behavioral regulation\n* activities of daily living\n* Enrolled in and able to participate in a two-week intensive therapy program consisting of approximately 2.5 hours per day\u002F 5 days per week\n\n  * Able to complete baseline and post-program clinical assessment using clinician-observed or caregiver-reported measures.\n  * Parent or legal guardian able to provide informed consent and participate in reporting functional outcomes when applicable.\n\nExclusion Criteria:\n\n* Medical instability or acute medical condition that would prevent safe participation in an intensive therapy program.\n* Severe uncontrolled seizure activity or other neurologic condition that would interfere with participation in structured therapeutic activities, as determined by the treating clinician.\n* Behavioral or psychological conditions that would prevent safe engagement in the therapy environment despite appropriate support.\n* Inability to attend or complete the full two-week intensive program.\n* Lack of sufficient baseline or post-intervention data to assess change in functional performance.\n* Concurrent participation in another structured intervention or clinical study that would confound interpretation of functional outcomes, at the discretion of the investigator.","4 Years","12 Years",{"count":117,"type":21},100,"OBSERVATIONAL","This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy (HIE), and chromosomal or genetic abnormalities.\n\nParticipants receive individualized therapy sessions for approximately 2.5 hours per day over a two week period. The intervention is not standardized but is tailored to each child's specific needs and may include components such as sensory integration, motor planning, reflex integration, oculomotor training, executive functioning activities, communication support, and other brain based therapeutic approaches.\n\nThe purpose of this study is to observe changes in functional abilities, including attention, motor coordination, emotional regulation, communication, and activities of daily living. Outcomes are assessed using clinician observation and parent reported changes before and after the intensive program, with limited follow-up when available.\n\nThis study does not assign participants to a specific treatment as part of a research protocol. Instead, it collects real world data from children already participating in a clinical therapy program to better understand potential benefits of intensive, individualized neurorehabilitation approaches.",[121,122,123,124,125,126,127,128,129,130,131,30,27,132,133,134,135,136,137,138,139,140,141],"Neurodevelopmental Disorders","Neurodevelopmental Disorders (NDD)","Neurodevelopmental Disorders and Developmental Abnormalities","Developmental Delay (Disorder)","Cerebral Palsy (CP)","Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment","Cerebral Palsy Infantile","Cerebral Palsy Spastic Hemiplegic","Cerebral Palsy, Dyskinetic","Autism Spectrum Disorder","Autism Spectrum Disorder (ASD","Traumatic Brain Injury (TBI)","Sensory Processing Disorder","Chromosomal Abnormalities","Genetic Disorders","Down Syndrome (Trisomy 21)","Fragile X Syndrome (FXS)","RETT Syndrome With Proven MECP2 Mutation","Williams Syndrome","22q11.2 Deletion Syndrome","Sensorimotor Integration",[143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,121,161,162,163,164,165,166],"Photobiomodulation","Low-Level Laser Therapy","Vibration Therapy","Tactile Stimulation","Cognitive Training","Behavioral Therapy","Intensive Therapy","Pediatric Neurorehabilitation","Multimodal Therapy","Neuroplasticity","Sensory Integration","Reflex Integration","Motor Planning","Executive Function","Emotional Regulation","Functional Outcomes","Activities of Daily Living","High Frequency Therapy","Rehabilitation","Child Development Disorders","Occupational Therapy","Physical Therapy Modalities","Early Intervention","Cognitive Therapy","2026-03-19",{"date":169,"type":37},"2026-03-25",{"date":171,"type":37},"2026-03-01",{"date":173,"type":21},"2036-12-30",{"name":175,"class":80},"Healing Hope International",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100574708","the-hienome-study-genome-sequencing-for-perinatal-hie-100574708","NCT06762795","The HIEnome Study: Genome Sequencing for Perinatal HIE","Inclusion Criteria:\n\n* Delivery ≥35w0d gestation\n* Diagnosed with moderate or severe HIE, or HIE with seizures\n* Undergoing total body cooling \u002F therapeutic hypothermia\n* Able to provide blood or buccal samples during birth hospitalization\n* Admitted to Texas Children's Hospital Main, West, or Woodlands NICU\n\nExclusion Criteria:\n\n* Parents\u002Ffamily not willing to allow participation\n* Inability to collect sufficient neonatal blood samples (in some circumstances, a buccal swab may be used as backup)","0 Days","1 Year",{"count":185,"type":21},25,[94],"Perinatal hypoxic-ischemic encephalopathy is a rare severe condition in which neonates present with encephalopathy and a clinical history suggestive of prenatal or perinatal hypoxic-ischemic injury. Emerging evidence suggests that genetic conditions are frequently identified in cases of perinatal HIE; however, it is unclear which neonates with this diagnosis warrant genetic testing. This study will offer clinical genome sequencing to neonates with HIE who are undergoing total body cooling (therapeutic hypothermia) and their parents.",[189,30,27],"Hypoxic Ischemic Encephalopathy of Newborn",[63,191,192],"Genetic testing","Genome sequencing","2025-09-25",{"date":195,"type":37},"2025-10-01",{"date":197,"type":37},"2025-05-15",{"date":199,"type":21},"2027-06-30",{"name":201,"class":80},"Baylor College of Medicine",2,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":211,"sex":17,"minAge":212,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":215,"conditions":216,"keywords":220,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":81},"100260086","immunoinflammatory-response-in-post-cardiac-arrest-syndrome-pcas-100260086","NCT02664831","Immunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS)","Immunoinflammatory and Metabolic Responses in Post Cardiac Arrest Syndrome (PCAS)","PCAS","Inclusion Criteria:\n\n* Aged 18 years or older\n* Admitted to the intensive care unit after cardiac arrest episode\n* Unresponsive after resuscitation\n\nExclusion Criteria:\n\n* Moribund \u002F actively dying at the time of evaluation\n* Informed consent cannot be obtained within 24 hours of resuscitation\n* Hemoglobin less than 7.0 g\u002FdL, active high-volume bleeding, or requiring a transfusion",true,"18 Years",{"count":214,"type":21},400,"This is a prospective, observational study to investigate molecular mechanisms mediating the systemic inflammatory process, and changes to metabolism, and their impact on brain injury, survival, and functional outcomes after cardiac arrest. Investigators have shown that cardiac arrest induces changes in the numbers and properties of circulating immune cells, shifting the balance towards a pro-inflammatory phenotype and there is increased interest in the inflammatory pathways and the signaling mechanisms through which they are modulated. Participants will undergo blood sampling during 7 days following cardiac arrest, and analyses performed. Patient characteristics, clinical circumstances, and outcomes will be recorded and their associations with these inflammatory pathways characterized.",[217,218,219,27],"Cardiac Arrest","Inflammation","Obesity",[221,222,223,224,225,226,227,31],"cardiac arrest","inflammation","immune","neuregulin","lymphocyte","neutrophil","brown adipose","2025-07-15",{"date":230,"type":37},"2025-07-18",{"date":232,"type":37},"2016-01",{"date":234,"type":21},"2028-01",{"name":236,"class":80},"MaineHealth",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":245,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":81},"100594847","severity-of-hypoxic-ischemic-encephalopathy-and-neurological-pupil-index-in-neonates-100594847","NCT07024771","Severity of Hypoxic Ischemic Encephalopathy and Neurological Pupil Index in Neonates","A Study On Association Between Neurological Pupil Index and Clinical Severity of Hypoxic Ischemic Encephalopathy In Neonates Admitted To Neonatal Neurocritical Care Unit","SHINE","Inclusion Criteria:\n\n* Neonates ≥35 weeks of GA, with Hypoxic ischemic encephalopathy admitted to neonatal neuro-intensive care unit at Alberta children's hospital, Calgary will be included in the study\n\nExclusion Criteria:\n\n* Infants with chromosomal abnormalities\u002F syndromic associations\n* Infants with ocular \u002F orbital injuries or structural anomalies of the eye obscuring the pupillometry measurement\n* Infants with inadequate pupillometry data \u002F EEG data",{"count":185,"type":21},"The goal of this observational study is to learn if the reactivity of a newborn's eye to light (measured as an index, using a new device -pupillometer) reflect the health of their brain recovering from disruption of blood\u002Foxygen supply during birth (Hypoxic Ischemic Encephalopathy-HIE). The main questions it aims to answer are:\n\n* With a decreasing reactivity index, does the chance of an abnormal electrical function of brain (noted by electroencephalography (EEG)) increase?\n* With a decreasing reactivity index, do the odds of an indicator of severe impact on brain health (abnormal brain imaging, seizures, feeding difficulty) increase? Participants will undergo eye examination using the pupillometer instead of the regular penlight, as part of their routine neurological examination. This will not change the way in which the newborn is being treated and managed medically.",[27],[249,250,251,252,253,67,254,255,256,257],"Neurological pupil index","Hypoxic ischemic encephalopathy","automated pupillometry","neonatal neurocritical care","severity of HIE","cooling therapy","NPi","seizures","EEG","2025-06-09",{"date":260,"type":37},"2025-06-17",{"date":262,"type":21},"2025-08",{"date":264,"type":21},"2026-06",{"name":266,"class":80},"University of Calgary",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":4},"100569461","neonates-with-hypoxic-ischemic-encephalopathy-hie-100569461","NCT06694545","Neonates With Hypoxic Ischemic Encephalopathy (HIE)","Role of Intravenous Magnesium Sulphate and Caffeine in Neonates With Hypoxic Ischemic Encephalopathy (HIE) in a Assiut University Hospital of Children","Inclusion Criteria:\n\n1. Neonates with suspected perinatal asphyxia APGAR score \\\u003C 3 at 5 min.\n2. Neonates whose mother did not receive MgSO4 or caffeine\n\nExclusion Criteria:\n\n1. Neonates with Apgar's score \\> 3 at 5 min\n2. Neonates with congenital malformations\n3. Neonates whose mother had general anasthesia","28 Days",{"count":276,"type":21},72,"Assessment of the potential neuroprotective effect of magnesium sulphate and caffeine in treating asphyxiated newborns and improvement of the neurological outcome of Hypoxic Ischemic Encephalopathy in Assiut university hospital of Children",[27],"2024-11-15",{"date":281,"type":37},"2024-11-19",{"date":283,"type":21},"2024-12-01",{"date":285,"type":21},"2026-01-31",{"name":287,"class":80},"Assiut University"]